First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

doi:10.1200/JCO.2007.14.8494

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 May 2008

Sequist Lecia V, Martins Renato G, Spigel David, Grunberg Steven M, Spira Alexander, Jänne Pasi A, Joshi Victoria A, McCollum David, Evans Tracey L, Muzikansky Alona, Kuhlmann Georgiana L, Han Moon, Goldberg Jonathan S, Settleman Jeffrey, Iafrate A John, Engelman Jeffrey A, Haber Daniel A, Johnson Bruce E, Lynch Thomas J

Abstract excerpt

PURPOSE: Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response in patients with non-small-cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). The multicenter iTARGET trial prospectively examined first-line gefitinib in advanced NSCLC patients harboring EGFR mutations and explored the significance of EGFR mutation subtypes and TKI resistance...

Topics

Adenocarcinoma
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Carcinoma, Large Cell
Carcinoma, Non-Small-Cell Lung
Central Nervous System Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Disease-Free Survival

ErbB Receptors

Female

Gefitinib

Humans

In Situ Hybridization, Fluorescence

Lung Neoplasms

Male

Middle Aged

Mutation

Source

Open in PubMed

Identifiers

PMID: 18458038
DOI: 10.1200/JCO.2007.14.8494

Genes

EGFR
MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-18458038-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.PMID 18458038Read ↗

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.Semantic proximity Read ↗

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.Semantic proximity Read ↗

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.Semantic proximity Read ↗

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.Semantic proximity Read ↗

Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database.Semantic proximity Read ↗

Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations.Semantic proximity Read ↗

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.Semantic proximity Read ↗

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.Semantic proximity Read ↗

Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.Semantic proximity Read ↗

Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.